The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
|Videos|December 15, 2020
Overview of the PIONEER Clinical Trial Program for Oral Semaglutide
Results from the PIONEER clinical trials program indicate that the first oral glucagon-like peptide-1 receptor agonist (GLP-1RA), oral semaglutide, provides effective glycemic control across a range of different patient populations.
Click PLAY to watch the video abstract.
Click
Click
Related to this article
A follicular lymphoma survivor shares axi-cel CAR T-cell therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improve quality of life.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5